Comparison · NCT02980276-89937dc0
Treatment vs Control: Maternal Morbidity - Postpartum Hemorrhage
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Treatment vs Control: Maternal Morbidity - Postpartum Hemorrhage. Trial comparisons, record NCT02980276-89937dc0. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02980276-89937dc0
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.195 | 0.151 | 0.247 | wilson | |
| Risk in group 2 | 0.24 | 0.193 | 0.296 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0458 | -0.116 | 0.025 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.81 | 0.584 | 1.12 | log | |
| Odds ratio, group 1 over group 2 | 0.763 | 0.503 | 1.16 | log | |
| Number needed to treat, for one fewer participant with the outcome on Treatment than on Control | 21.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Treatment | Participants randomised to the treatment arm received active metformin in addition to standard care. Metformin tablets will be titrated according to a dosing schedule to achieve the pre-specified glucose targets. Tablets will be in 500mg doses and will commence at 1 tablet per day (500mg) increasing to a maximum of 5 tablets per day (2500mg). | 51 | 262 | OG000 |
| Group 2 | Control | Participants randomised to the placebo arm received placebo in addition to standard care. Placebo will be titrated according to the dosing schedule to achieve the pre-specified glucose targets. Placebo tablets will commence at 1 tablet per day and will be increased to a maximum of 5 tablets per day over 10 days as with the treatment group. | 63 | 262 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Maternal Morbidity - Postpartum Hemorrhage
- Description
- Time frame
- From delivery through 6 weeks postpartum.
- Population
Source ClinicalTrials.gov
Trial
- Title
- RCT Metformin for Reduction of Gestational Diabetes Mellitus Effects
- NCT number
- NCT02980276
- Phases
- PHASE3
- Conditions
- Gestational Diabetes
- Interventions
- Metformin Hydrochloride, Placebo
- Lead sponsor
- National University of Ireland, Galway, Ireland
- Results first posted
- 2025-03-17
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02980276?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02980276-89937dc0